2、金固股份：收到全球龙头车企美国产乘用车车轮产品定点通知。 一、增持、股权转让、回购 1、上海莱士：控股股东海盈康拟2.5亿元-5亿元增持公司股份。 2、科德教育：公司控股股东签署了《股份转让协议》，十堰市国资委将成为公司实际控制人。 3、纳芯微：股东询价转让定价为163.15元/股。 4、盛弘股份：本次询价转让的价格为27.76元/股。 5、震有科技：拟注销105.54万股回购股份。 6、中复神鹰：鹰游集团拟向海南鹰游转让22.22%公司股份，转让价格21.02元/股。 二、对外投资、日常经营 1、万科A：与深圳地铁集团签署《不超过人民币42亿元借款合同》，并收到42亿元借款。同时约定以 不超60亿元万物云股票作为与深铁集团借款合同质押物。 晚间公告 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 3、龙旗科技：筹划发行H股股票并在香港联合交易所有限公司上市。 4、浙江荣泰：拟在浙江嘉兴投资设立全资子公司浙江荣泰智能机器人有限公司，投资金额2000万。 5、英维克：拟投资不低于10亿元建设精密温控节能设备研发中心及生产基地项目。 6、恒瑞医药：H股发行价格确定为每股44. ...

【品大事】 恒瑞医药：H股发行价格确定为每股44.05港元 恒瑞医药(600276)公告，公司正在进行发行H股股票并在香港联交所主板挂牌上市的相关工作。公司已 确定此次H股发行的最终价格为每股44.05港元（不包括1%经纪佣金、0.0027%香港证券及期货事务监察 委员会交易征费、0.00565%香港联交所交易费及0.00015%香港会计及财务汇报局交易征费）。公司此 次发行的H股预计于2025年5月23日在香港联交所主板挂牌并开始上市交易。 5月21日晚间，沪深两市多家上市公司发布公告，以下是第一财经对一些重要公告的汇总，供投资者参 考。 【签大单】 万东医疗：选举马赤兵为董事长 万东医疗(600055)公告，胡自强因个人原因辞去公司董事长、董事会战略委员会委员、董事会薪酬与考 核委员会委员职务，辞任生效后将不再担任公司任何职务。公司召开董事会会议审议通过相关议案，同 意选举马赤兵为第十届董事会董事长。截至目前，马赤兵未持有公司股份，除担任控股股东美的集团美 的医疗业务板块负责人外，与公司其他董事、监事、高管不存在关联关系。 四连板天汽模：不存在未披露的重大事项 四连板天汽模(002510)披露公司股票交易 ...

证券代码：002252 证券简称：上海莱士 公告编号：2025-043 上海莱士血液制品股份有限公司 关于控股股东增持股份计划的公告 公司控股股东海盈康（青岛）医疗科技有限公司保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 特别提示： 上海莱士血液制品股份有限公司（以下简称"上海莱士"或"公司"）控股股东 海盈康（青岛）医疗科技有限公司（以下简称"海盈康"）基于对公司未来发展的 信心和长期投资价值的认同，增强投资者信心，计划自本公告披露之日起6个月 内（除法律、法规及深圳证券交易所业务规则等有关规定不准增持公司股票的期 间之外），通过深圳证券交易所交易系统以集中竞价交易方式增持公司股份。本 次计划增持总金额不低于人民币25,000万元，且不超过人民币50,000万元（均含 本数且不包含交易费用）（以下简称"本次增持计划"）。本次增持计划不设置价 格区间。 公司于近日收到控股股东海盈康《关于增持上海莱士血液制品股份有限公司 股份计划的告知函》，现将相关情况公告如下： 一、计划增持主体的基本情况 1、增持主 ...

证券代码：002252 证券简称：上海莱士 公告编号：2025-042 上海莱士血液制品股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在增加、变更、否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 3、本次会议提案涉及股东大会特别决议事项，按照《公司章程》规定，本次特 别决议事项需经出席会议股东（包括股东代理人）所持表决权 3/4 以上表决同意后方 可通过。 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间为：2025 年 5 月 20 日（星期二）14:00； 网络投票时间为：2025 年 5 月 20 日（星期二）； 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 20 日的交易时间，即 9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2025 年 5 月 20 日 9:15 至 15:00 期间的任意时 间； 2、现场会议召开地点：上海市 ...

北京市金杜（青岛）律师事务所 关于上海莱士血液制品股份有限公司 2024 年度股东大会之 法律意见书 致：上海莱士血液制品股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受上海莱士血液制品 股份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监 督管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民 共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、 规章、规范性文件和现行有效的《上海莱士血液制品股份有限公司章程》（以下 简称《公司章程》）的有关规定，指派律师出席了公司于 2025 年 5 月 20 日召 开的 2024 年年度股东大会（以下简称本次股东大会），并就本次股东大会相关 事项出具本法律意见书。 1. 经公司 2024 年第三次临时股东大会审议通过的《公司章程》； 2. 公司 2024 年 12 月 28 日刊登于巨潮资讯网及深圳证券交易所网站的《上 海莱士血液制品股份有限公司第六届董事会第六 ...

Summary of the Conference Call for Hualan Biological Engineering Company Overview - The conference call discusses Hualan Biological Engineering, a company in the blood products industry, focusing on its performance, strategies, and market dynamics in 2025. Key Points Industry and Market Dynamics - The blood products industry is facing significant price pressure in 2025, with Hualan's product prices remaining stable compared to competitors who have reduced their prices significantly [2][3][4] - The demand for human albumin in China continues to grow, with imports accounting for 68% of the market share in 2024, and the industry is expected to maintain a growth rate of around 10% [3][10][11] - The increase in import tariffs on human albumin by 10% has raised costs, potentially leading to higher end-user prices [2][8] Company Performance - Hualan achieved continuous growth in production volume and profits by stabilizing product prices and ensuring supply to hospitals during the pandemic [2][3] - The company’s first-quarter performance in 2025 exceeded industry averages due to stable pricing strategies and effective supply chain management [3][4] - The company’s revenue from blood products is projected to exceed 1.1 billion yuan in 2025, with vaccine business profits expected to reach 300 million yuan, marking a 50% increase [3][35] Pricing and Supply Chain Management - Hualan has maintained stable factory prices for human albumin and other products, ensuring a consistent supply to hospitals and pharmacies [2][5][6] - The company has implemented strategies to monitor and manage distributors to prevent supply shortages that could lead to market share loss [5][6] - The factory price of human albumin has remained stable, with a maximum price cap of 378 yuan, despite external market fluctuations during the pandemic [6][7] Future Growth and Product Development - Hualan is set to launch a high-concentration product in 2026, priced 50% higher than standard products, focusing on domestic supply first [3][16][17] - The company is not currently considering exporting blood products due to strong domestic demand and the profitability of local sales [18] - The monoclonal antibody business is expected to improve, with the first product, Bevacizumab, anticipated to break even in 2025 [20] Challenges and Strategic Adjustments - The company faces challenges from increased competition and pricing pressures in the blood products market, but it is well-positioned due to its established supply chains and market strategies [15][19] - Hualan's vaccine business, which faced difficulties in 2024, is expected to recover significantly in 2025, contributing positively to overall profits [25][35] Financial Performance and Projections - In 2024, Hualan reported a total profit of 1.08 billion yuan, with blood products contributing 940 million yuan [34] - The company anticipates maintaining a net profit margin of around 30% in the future, with potential for growth if other product lines perform well [34][35] Conclusion - Hualan Biological Engineering is navigating a challenging market environment with strategic pricing, supply chain management, and product development initiatives aimed at sustaining growth and profitability in the blood products and vaccine sectors [2][3][35]

Group 1 - China has adjusted the tariff rate on imports from the US to 10%, suspending the previously implemented 24% rate for 90 days, significantly lower than the peak of 125% seen in April [1] - The adjustment in tariffs is expected to reduce the price pressure on imported blood products and slow down the expectations for domestic alternatives [1][2] - Major domestic blood product companies, including TianTan Bio, TaiBang Bio, and Hualan Bio, account for approximately 80% of the domestic plasma collection volume [1] Group 2 - The domestic market for human albumin, which constitutes about 70% of blood product usage, is heavily reliant on imports, with over 60% of the market share [2] - The price of imported human albumin products is currently higher than that of domestic products, but the tariff reduction to 10% will lessen the price advantage of imports [2][3] - The ongoing trade friction presents an opportunity for domestic products to penetrate hospital markets and adjust revenue structures, as hospitals may diversify their suppliers [3] Group 3 - The domestic blood product industry is currently in a downturn, with competition intensifying due to increased supply and price linkage effects [4] - Unlike the domestic market, where human albumin is predominant, international markets utilize immunoglobulin and coagulation factor products more extensively [5] - Domestic blood product companies face technological gaps compared to international leaders, limiting their product range and production capabilities [5]

证券代码：002252 证券简称：上海莱士 公告编号：2025-041 一、增持计划主体的基本情况 上海莱士血液制品股份有限公司 关于控股股东增持公司股份计划实施完成的公告 公司控股股东海盈康（青岛）医疗科技有限公司保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 特别提示： 1、增持计划的主要内容：上海莱士血液制品股份有限公司（"上海莱士"、 "公司"）于2025年3月4日披露了《关于控股股东增持股份计划的公告》（公告编 号：2025-020），基于对未来发展的信心和长期投资价值的认同，增强投资者信 心，控股股东海盈康（青岛）医疗科技有限公司（"海盈康"）计划自本次增持计 划公告披露之日起6个月内（除法律、法规及深圳证券交易所业务规则等有关规 定不准增持公司股票的期间之外），通过深圳证券交易所交易系统以集中竞价交 易方式增持公司股份，拟增持金额不低于人民币25,000万元，且不超过人民币 50,000万元（均含本数且不包含交易费用）（"本次增持计划"）。本次增持计 划不设置增持股份价格区间，增持主体基于 ...

上海莱士（002252）公告，控股股东海盈康于2025年3月7日至2025年5月9日期间，通过深圳证券交易所 系统以集中竞价方式累计增持公司股份7304.22万股，占目前公司总股本的1.10%，增持总金额约为人民 币5亿元(不含交易费用)。本次增持计划已实施完毕。增持前海盈康持有公司21.11%股份，增持后持股 比例增至22.21%。 ...

Group 1 - The Shanghai Composite Index opened high and the CSI 300 Pharmaceutical and Biotechnology Index reported 7624.71 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 4.46% in the past month, 3.56% in the past three months, and 2.43% year-to-date [1] - The index is designed to reflect the overall performance of different industry companies within the CSI 300 Index, categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings of the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.5%), WuXi AppTec (15.98%), Pian Zai Huang (6.77%), Yunnan Baiyao (5.51%), Kelun Pharmaceutical (4.73%), New Horizon (3.69%), East China Pharmaceutical (3.68%), Shanghai Raist (3.39%), Changchun High-tech (3.33%), and Fosun Pharma (3.23%) [1] - The market segment of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.75% and the Shenzhen Stock Exchange accounts for 36.25% [2] - In terms of industry composition, chemical drugs account for 43.27%, pharmaceutical and biotechnology services for 21.11%, traditional Chinese medicine for 19.35%, and biological drugs for 16.27% [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted along with the periodic sample adjustments, which are fixed until the next scheduled adjustment unless a temporary adjustment is required [2] - Special events affecting sample companies may lead to changes in industry classification, and companies that are delisted will be removed from the index [2]